These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22612239)

  • 1. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
    Auger S; Duny Y; Rossi JF; Quittet P
    Br J Haematol; 2012 Aug; 158(3):386-98. PubMed ID: 22612239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
    Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Derumeaux H; Adoue D
    Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
    Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N; Evangelista ML; Amadori S; Stasi R
    Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reemergence of Splenectomy for ITP Second-line Treatment?
    Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
    Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F; Ruggeri M
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
    Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
    Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
    Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
    Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment outcome of immune thrombocytopenia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2012 Oct; 153(41):1613-21. PubMed ID: 23045311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.